Does not ↓ BP or heart rate; remainder of mechanism is not known.
Therapeutic effects:
Decreased frequency of angina.
Classifications⬆⬇
Therapeutic Classification: antianginals
Pharmacokinetics⬆⬇
Absorption: Highly variable.
Distribution: Unknown.
Metabolism/Excretion: Metabolized by the liver primarily by the CYP3A isoenzyme and to a lesser extent by the CYP2D6 isoenzyme; <5% excreted unchanged in urine and feces.
Half-Life: 7 hr.
Canadian Brand Names⬆⬇
Corzyna
Time/Action Profile⬆⬇
(plasma concentrations)
ROUTE
ONSET
PEAK
DURATION
PO
unknown
2–5 hr
12 hr
Patient/Family Teaching⬆⬇
Explain purpose and side effects of medication to patient. Advise to read Patient Information before starting therapy.
If dose is missed, instruct patient to take the usual dose at the next scheduled time; do not double doses. Explain that ranolazine is used for chronic therapy and will not help an acute angina episode.
Advise patient to avoid grapefruit juice and grapefruit products when taking ranolazine.
May cause dizziness and light-headedness. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
Advise patient to notify health care professional if fainting occurs.
Inform patient that ranolazine may cause changes in the ECG. Patient should inform health care professional if they have a personal or family history of QTc interval prolongation, congenital long QT syndrome, or proarrhythmic conditions such as hypokalemia.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Rep: Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.
